Celcuity (CELC) Could Be 40% Undervalued After REVTORPYK FDA Filing
Celcuity (CELC) stock is back in focus after the company filed a supplemental New Drug Application with the FDA for REVTORPYK, backed by positive Phase 3 VIKTORIA-1 data in PIK3CA mutant advanced breast cancer.
Celcuity’s latest sNDA news has arrived alongside a 1-month share price return of 9.67% and a 90-day share price return of 4.03%, while the share price is down 4.33% year to date. However, the 1-year total shareholder return of 77.49% and the very large 3-year total shareholder return suggest longer term momentum has been strong.
Scan beyond Celcuity and assess other high potential biotechs showing strong total return profiles with our curated 20 high quality undiscovered gems.
After Celcuity stock's sharp rerating on the REVTORPYK update, the story now hinges on price. Do the current multiples and implied upside still leave enough room for buyers, given the company’s risks and cash burn profile?
Most Popular Narrative: 40.3% Undervalued
The most followed narrative on Celcuity currently anchors fair value at $161.09 per share compared with the last close of $96.20. That gap rests on a set of aggressive but clearly defined assumptions about future revenue, margins and earnings power.
Celcuity currently has no revenue. Analysts are forecasting revenue to reach $817.9 million by June 2029.
Want to see what has to happen for Celcuity to grow from zero sales to that level in just a few years? The narrative leans on sharp earnings expansion and a rich future profit multiple that is normally reserved for established sector leaders. Curious which exact revenue and margin paths need to line up to support that $161.09 fair value?
Result: Fair Value of $161.09 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Celcuity’s story could shift quickly if upcoming VIKTORIA-2 results disappoint or if regulators delay or alter approvals. Such developments would challenge today’s optimistic revenue path.
Find out about the key risks to this Celcuity narrative.
Next Steps
With Celcuity’s outlook reflecting both confidence and concern, it makes sense to move quickly and weigh the full picture for yourself using the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Celcuity?
If you stop with Celcuity, you risk missing other stocks with strong potential, clear financial traits and return profiles that may fit your style even better.
- Target steadier compounding by reviewing a 75 resilient stocks with low risk scores that highlights companies with more resilient risk scores.
- Pursue value opportunities by scanning a 54 high quality undervalued stocks that focuses on quality businesses trading below their estimated worth.
- Strengthen your foundation by checking a list of solid balance sheet and fundamentals (52 results) that surfaces companies with healthier debt and liquidity profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com